Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 1;76(6):665-671.
doi: 10.1001/jamaneurol.2019.0330.

Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden

Affiliations

Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden

Omid Beiki et al. JAMA Neurol. .

Abstract

Importance: Clinicians' experience and findings from recent natural history studies suggest that multiple sclerosis (MS) may now be running a more slowly progressing course than before.

Objective: To investigate whether the risk of reaching MS disability milestones has changed over the last decade in Sweden.

Design, setting, and participants: A nationwide population-based retrospective cohort study. By April 2017, 12 512 patients with available information on demographics, MS phenotype, and date of MS onset and diagnosis were registered in the Swedish MS Registry of which 7331 patients with at least 2 recorded Expanded Disability Status Scale scores (EDSS) and diagnosed between January 1995 and December 2010 were included. No further exclusion criteria were applied. Patients were followed up until December 2016 with a median duration follow-up of 8.5 (interquartile range, 4.7-13.8) years. Statistical analysis began in April 2017.

Main outcomes and measures: Patients were followed up from MS onset date to the date of sustained EDSS 3.0, 4.0, and 6.0. To handle interval-censored observations, a Weibull model was fit, and the change in the risk of EDSS 3.0, 4.0, and 6.0 over calendar years was estimated and hazard ratios (HRs) with corresponding CIs were calculated.

Results: Of 7331 patients, 5196 (70.9%) were women, and the mean (SD) age at diagnosis was 38.3 (11.7) years. Adjusting for sex, number of clinic visits, diagnostic delay, and onset age, a 3% decrease per calendar year of diagnosis for the risk of sustained EDSS 3.0 (HR, 0.97; 95% CI, 0.96-0.97), a 6% decrease for the risk of EDSS 4.0 (HR, 0.94; 95% CI, 0.93-0.95), and a 7% decrease for the risk of EDSS 6.0 (HR, 0.93; 95% CI, 0.91-0.94) among patients with relapsing-onset MS was found. The trends were not significant for patients with progressive-onset MS (EDSS 3.0: HR, 1.01; 95% CI, 0.98-1.03; EDSS 4.0: HR, 1.00; 95% CI, 0.98-1.02; EDSS 6.0: HR, 1.00; 95% CI, 0.98-1.02).

Conclusions and relevance: Risk of reaching major disability milestones has significantly decreased over the last decade in patients with relapsing-onset MS in Sweden. Several factors could potentially be responsible for this observation. However, given that no change was seen in disability accrual of patients with progressive-onset MS and the absence of efficacious treatment option in this group, increased use of more efficacious disease-modifying treatments could be a possible driver of this change.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Beiki has received salary for epidemiological consultation for pharmaceutical companies from Cognizant Technology Solutions. Dr Hillert has received honoraria for serving on advisory boards for Biogen, Sanofi Genzyme, and Novartis, speaker’s fees from Biogen, Novartis, Merck Serono, Bayer Schering, Teva Pharmaceutical Industries, and Sanofi Genzyme; and has served as principal investigator for projects or has received unrestricted research support from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Sanofi Genzyme, and Bayer Schering. No other disclosures were reported.

Figures

Figure.
Figure.. Censoring and Truncation in Longitudinal Analysis
Possible scenarios and pitfalls of patient follow-up are shown in a time-to-event analysis. In time-to-event settings, risks (hazard) of reaching an outcome are compared between groups of patients over follow-up time. A distinguishing feature of this analysis is its ability to incorporate the effect of censoring or loss to follow-up in the estimation of hazard. Censoring occurs when information about an individual’s follow-up time is incomplete. Left censoring, which happens when the outcome occurs before start of follow-up, is a common problem in studies of multiple sclerosis as a proportion of individuals are excluded owing to the occurrence of outcome before the start of follow-up time. The main problem in our data is left-censored observation that indicates disability milestone had already happened.

References

    1. Steinvorth SM, Rover C, Schneider S, Nicholas R, Straube S, Friede T. Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. Mult Scler. 2013;19(12):1580-1586. doi:10.1177/1352458513481009 - DOI - PubMed
    1. Röver C, Nicholas R, Straube S, Friede T. Changing EDSS progression in placebo cohorts in relapsing MS: a systematic review and meta-regression. PLoS One. 2015;10(9):e0137052. doi:10.1371/journal.pone.0137052 - DOI - PMC - PubMed
    1. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004-2015. doi:10.1212/WNL.0b013e3181e3973f - DOI - PubMed
    1. Weinshenker BG, Bass B, Rice GP, et al. . The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain. 1989;112(pt 1):133-146. doi:10.1093/brain/112.1.133 - DOI - PubMed
    1. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116(pt 1):117-134. doi:10.1093/brain/116.1.117 - DOI - PubMed

Publication types

Substances